RxDoctor Payments Data

Daniel Poole, MD

Neurology · Goldsboro, NCNPI 1205875234

Payments from drug & device makers

$12,672in general payments, 2019–2025

Across 731 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$889
  • Lundbeck LLC$751
  • AstraZeneca$697
  • Teva Pharmaceuticals USA, Inc.$688
  • AbbVie$685
  • Genentech USA, Inc.$674
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$570%
  • Food & beverage$12,50399%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis60$889
Lundbeck LLC38$751
AstraZeneca(2 entities)39$697
Teva Pharmaceuticals USA, Inc.46$688
AbbVie(2 entities)43$685
Genentech USA, Inc.43$674
UCB, Inc.22$515
Neurocrine Biosciences, Inc.33$499
Lilly USA, LLC32$456
SK Life Science, Inc.17$391
Amneal Pharmaceuticals LLC23$341
Supernus Pharmaceuticals, Inc.21$316
EMD Serono, Inc.17$302
Neurelis, Inc.17$287
Eisai Inc.17$282
Merck13$258
Boehringer Ingelheim14$241
Aucta Pharmaceuticals, Inc.17$239
Regeneron Healthcare Solutions, Inc.11$234
Amgen11$229
TG Therapeutics, Inc.7$218
GSK14$207
MDD US Operations, LLC11$199
Biogen9$191
Bristol Myers Squibb12$181
Impel Pharmaceuticals Inc.9$174
Novo Nordisk9$145
Johnson & Johnson4$142
Biohaven Pharmaceutical Holding Company Ltd.8$139
Pfizer9$132
Mallinckrodt Hospital Products Inc.6$120
Biohaven Pharmaceuticals, Inc.7$100
Amarin Pharma, Inc.6$87
Recordati_rare_diseases_inc.4$86
Acorda Therapeutics, Inc6$84
Banner Life Sciences, LLC3$84
Avion Pharmaceuticals4$73
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$73
Baxter Healthcare3$71
Averitas Pharma Inc.2$69
Argenx US, Inc.2$60
Avanir Pharmaceuticals, Inc.4$59
Grifols USA, LLC3$56
Aprecia Pharmaceuticals, LLC3$48
Abbott2$44
Corcept Therapeutics2$44
Kyowa Kirin, Inc.2$44
Sanofi1$43
Vertical Pharmaceuticals, LLC2$41
Inspire Medical Systems, Inc.1$39
Adamas Pharmaceuticals, Inc.3$39
Sunovion Pharmaceuticals Inc.2$37
Otsuka America Pharmaceutical, Inc.2$35
Inogen, Inc.2$35
Cequr Corporation2$34
Advanced Respiratory, Inc2$33
Axsome Therapeutics, Inc.2$32
Sanofi-aventis U.S. LLC1$30
Dexcom, Inc.2$29
Verona Pharma, Inc.1$29

How this compares

$12,672 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$111,382
Medicare patients
570
Services billed
985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab90$853,637
VumerityDiroximel Fumarate21$177,064
Avonex Pen (4 Pack)Interferon Beta-1a17$140,772
AustedoDeutetrabenazine13$140,142
Aimovig AutoinjectorErenumab-Aooe123$98,791
NuplazidPimavanserin Tartrate14$68,515
MysolinePrimidone11$42,234
XcopriCenobamate24$32,921
LamictalLamotrigine31$31,900
RytaryCarbidopa/Levodopa23$31,251
KeppraLevetiracetam13$29,777
Nurtec OdtRimegepant Sulfate21$27,556
Emgality PenGalcanezumab-Gnlm31$26,436
ValtocoDiazepam16$21,075
Lacosamide128$20,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$191$177,06421 claims
Teva Pharmaceuticals USA, Inc.Austedo$688$140,14213 claims
SK Life Science, Inc.Xcopri$391$32,92124 claims
GSKLamictal$207$31,90031 claims
Amneal Pharmaceuticals LLCRytary$341$31,25123 claims
PfizerNurtec Odt$132$27,55621 claims
Neurelis, Inc.Valtoco$287$21,07516 claims
AbbVieUbrelvy$685$15,15415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.

Other neurology in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →